Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 juin 2026 06h00 HE | Source: TISSIUM

TISSIUM secures €60 million to support commercial and clinical activities and platform expansion

€30 million Series D2 financing completed with participation from leading new and existing international investorsUp to €30 million financing facility secured from the European Investment Bank Paris,...
24 juin 2026 06h00 HE | Source: TISSIUM

TISSIUM sécurise 60 millions d'euros pour soutenir ses activités commerciales, cliniques et l'expansion de sa plateforme

Financement de Série D2 de 30 millions d'euros avec la participation d'investisseurs internationaux de premier plan, nouveaux et historiquesMise en place d’une facilité de financement pouvant...
15 juin 2026 13h15 HE | Source: TISSIUM

TISSIUM Selected to the French Tech Next40 Program

Paris, France, June 15, 2026 – TISSIUM, a medical technology company pioneering biomorphic programmable polymers for tissue reconstruction, today announced its selection to the French Tech...
15 juin 2026 13h15 HE | Source: TISSIUM

TISSIUM lauréat du programme French Tech Next40

Paris, France, le 15 juin 2026 – TISSIUM, société de medtech spécialisée dans le développement de polymères programmables biomorphiques pour la reconstruction des tissus, annonce aujourd'hui son...
05 mai 2026 13h15 HE | Source: TISSIUM

TISSIUM APPOINTS MARC QUARTULLI AS VICE PRESIDENT OF CLINICAL AFFAIRS

Paris, France, Cambridge, USA, May 5th, 2026 – TISSIUM, a Medical Technology company pioneering biomorphic programmable polymers for tissue reconstruction, announced today it has appointed Marc...
18 mars 2026 10h00 HE | Source: TISSIUM

TISSIUM® ANNOUNCES PUBLICATION OF FIRST-IN-HUMAN CLINICAL RESULTS OF THE COAPTIUM® CONNECT SYSTEM FOR ATRAUMATIC SUTURELESS NERVE REPAIR IN JHSGO

Paris, France, Cambridge, USA, March 18, 2026 – TISSIUM, a Medical Technology company pioneering biomorphic programmable polymers for tissue reconstruction, is pleased to announce the publication of...
28 nov. 2025 12h45 HE | Source: TISSIUM

TISSIUM Announces First Commercial Use of COAPTIUM® CONNECT for Peripheral Nerve Repair in the United States

Paris, France, Cambridge, USA, November 28, 2025 – TISSIUM, a Medical Technology company pioneering biomorphic programmable polymers for tissue reconstruction, announced today the ﬁrst commercial use...
05 juin 2025 04h00 HE | Source: TISSIUM

TISSIUM selected for the French Tech 120 Program

Paris, France, June 5, 2025 -- TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the sixth year in a row in the French Tech...
05 juin 2025 04h00 HE | Source: TISSIUM

TISSIUM lauréat du French Tech 120

Paris, France, le 5 juin 2025 -- TISSIUM, société de medtech spécialisée dans le développement de polymères programmables biomorphiques pour la reconstruction des tissus, confirme sa place, pour la...
02 avr. 2025 12h45 HE | Source: TISSIUM

TISSIUM Announces Clinical Results of COAPTIUM® CONNECT System for Atraumatic Sutureless Nerve Repair

Paris, France, Cambridge, USA, April 2nd, 2025 - TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, is proud to unveil clinical data...